SummitTX Capital L.P. Buys New Position in CAMP4 Therapeutics Corporation $CAMP

SummitTX Capital L.P. bought a new stake in shares of CAMP4 Therapeutics Corporation (NASDAQ:CAMP) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 339,521 shares of the Wireless communications provider’s stock, valued at approximately $1,497,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. China Universal Asset Management Co. Ltd. bought a new position in shares of CAMP4 Therapeutics in the 4th quarter worth $61,000. Jefferies Financial Group Inc. bought a new stake in shares of CAMP4 Therapeutics during the 4th quarter worth $70,000. State Street Corp lifted its holdings in shares of CAMP4 Therapeutics by 52.7% during the 4th quarter. State Street Corp now owns 39,700 shares of the Wireless communications provider’s stock worth $243,000 after acquiring an additional 13,700 shares during the last quarter. Bank of America Corp DE purchased a new position in CAMP4 Therapeutics in the fourth quarter worth $86,000. Finally, OMERS ADMINISTRATION Corp bought a new position in CAMP4 Therapeutics in the fourth quarter valued at $115,000.

CAMP4 Therapeutics Stock Down 4.4%

Shares of NASDAQ:CAMP opened at $3.27 on Thursday. The stock has a market cap of $169.81 million, a PE ratio of -1.39 and a beta of 0.10. The company’s fifty day moving average is $4.07 and its 200 day moving average is $4.39. CAMP4 Therapeutics Corporation has a 52 week low of $1.32 and a 52 week high of $7.75.

CAMP4 Therapeutics (NASDAQ:CAMP) last posted its quarterly earnings results on Thursday, May 7th. The Wireless communications provider reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.11). CAMP4 Therapeutics had a negative net margin of 2,193.72% and a negative return on equity of 194.74%. The business had revenue of $1.29 million for the quarter. Sell-side analysts anticipate that CAMP4 Therapeutics Corporation will post -0.84 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on CAMP shares. Rodman & Renshaw started coverage on CAMP4 Therapeutics in a research report on Tuesday, April 14th. They set a “buy” rating and a $7.00 price target on the stock. Zacks Research cut CAMP4 Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 15th. Leerink Partners increased their price objective on CAMP4 Therapeutics from $8.00 to $9.00 and gave the company an “outperform” rating in a research report on Thursday, April 2nd. JPMorgan Chase & Co. upgraded CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $5.00 to $9.00 in a research report on Tuesday, June 16th. Finally, Weiss Ratings lowered CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, May 21st. Seven investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat, CAMP4 Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $8.36.

CAMP4 Therapeutics Profile

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.